NCT05745454View on ClinicalTrials.gov

A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors

NANot yet recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

BIOLOGICAL

HER2-E-CART cells

E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein

All Listed Sponsors

lead

su haichuan

OTHER